ABS-1230
KCNT1-related epilepsies (e.g., Developmental and Epileptic Encephalopathies)
PreclinicalActive
Key Facts
Indication
KCNT1-related epilepsies (e.g., Developmental and Epileptic Encephalopathies)
Phase
Preclinical
Status
Active
Company
About Actio Biosciences
Actio Biosciences is a private, preclinical-stage biotech pioneering a 'Rare-to-Common' drug development strategy. The company uses human genetic insights from monogenic rare diseases to identify and validate high-confidence drug targets, aiming to de-risk development and expand therapies into broader common disease populations. Its lead program, ABS-1230, is a selective inhibitor of KCNT1 for epilepsy disorders, with recent preclinical data showing significant seizure reduction. Actio's approach positions it at the intersection of precision medicine and scalable therapeutic development.
View full company profile